147,700 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Talaria Asset Management Pty Ltd

Talaria Asset Management Pty Ltd purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 147,700 shares of the biopharmaceutical company's stock, valued at approximately $13,643,000. Gilead Sciences accounts for about 3.5% of Talaria Asset Management Pty Ltd's portfolio, making the stock its 10th biggest position.

A number of other institutional investors also recently added to or reduced their stakes in GILD. ABLE Financial Group LLC bought a new stake in Gilead Sciences during the fourth quarter worth approximately $234,000. LM Advisors LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $1,110,000. Leigh Baldwin & CO. LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $430,000. Ameriflex Group Inc. purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $264,000. Finally, Ascent Group LLC lifted its holdings in shares of Gilead Sciences by 26.6% during the fourth quarter. Ascent Group LLC now owns 21,108 shares of the biopharmaceutical company's stock valued at $1,950,000 after purchasing an additional 4,435 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,929 shares of company stock valued at $5,644,780. Company insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on GILD shares. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Wells Fargo & Company upped their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Bank of America upped their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded down $0.65 during midday trading on Wednesday, hitting $108.44. 4,591,543 shares of the company were exchanged, compared to its average volume of 7,722,873. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm has a market cap of $134.89 billion, a P/E ratio of 293.08, a PEG ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The firm has a 50 day simple moving average of $105.36 and a 200-day simple moving average of $100.57.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same period last year, the firm earned ($1.32) EPS. The business's revenue for the quarter was down .3% on a year-over-year basis. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.91%. Gilead Sciences's payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.